Oncology Reviews最新文献_第7页

Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy. 膜包埋药物外排ABC转运体在肿瘤化疗中的作用。

IF 3.6

Oncology Reviews Pub Date : 2020-07-06 DOI: 10.4081/oncol.2020.448

Sonu Kumar Gupta, Priyanka Singh, Villayat Ali, Malkhey Verma

{"title":"Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy.","authors":"Sonu Kumar Gupta, Priyanka Singh, Villayat Ali, Malkhey Verma","doi":"10.4081/oncol.2020.448","DOIUrl":"https://doi.org/10.4081/oncol.2020.448","url":null,"abstract":"One of the major problems being faced by researchers and clinicians in leukemic treatment is the development of multidrug resistance (MDR) which restrict the action of several tyrosine kinase inhibitors (TKIs). MDR is a major obstacle to the success of cancer chemotherapy. The mechanism of MDR involves active drug efflux transport of ABC superfamily of proteins such as Pglycoprotein (P-gp/ABCB1), multidrug resistance-associated protein 2 (MRP2/ABCC2), and breast cancer resistance protein (BCRP/ABCG2) that weaken the effectiveness of chemotherapeutics and negative impact on the future of anticancer therapy. In this review, the authors aim to provide an overview of various multidrug resistance (MDR) mechanisms observed in cancer cells as well as the various strategies developed to overcome these MDR. Extensive studies have been carried out since last several years to enhance the efficacy of chemotherapy by defeating these MDR mechanisms with the use of novel anticancer drugs that could escape from the efflux reaction, MDR modulators or chemosensitizers, multifunctional nanotechnology, and RNA interference (RNAi) therapy.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"14 2","pages":"448"},"PeriodicalIF":3.6,"publicationDate":"2020-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/21/onco-14-2-448.PMC7358983.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38162779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 34

Oral microbiota and oral cancer: Review. 口腔微生物群与口腔癌:综述。

IF 3.6

Oncology Reviews Pub Date : 2020-07-06 DOI: 10.4081/oncol.2020.476

Mariam Z Kakabadze, Teona Paresishvili, Lia Karalashvili, David Chakhunashvili, Zurab Kakabadze

{"title":"Oral microbiota and oral cancer: Review.","authors":"Mariam Z Kakabadze, Teona Paresishvili, Lia Karalashvili, David Chakhunashvili, Zurab Kakabadze","doi":"10.4081/oncol.2020.476","DOIUrl":"10.4081/oncol.2020.476","url":null,"abstract":"In this review, we draw attention and discuss the risk factors and causes of the development of oral squamous cell carcinoma (OSCC) focusing on oral microbiota. Recently, a breakthrough in the study of cancer has been the discovery of the relationship between the presence of certain types of bacteria and the development of cancer in the human body. Studies have shown that, Porphyromonas gingivalis (P. gingivalis) bacteria that is responsible for the destructive processes in the oral cavity, could play an important role in the development of OSCC. In our continuing search for bacteria that causes oral squamous cell carcinoma, we came across the Pseudomona aeruginosa, which due to its metabolite properties, may play important role in carcinogenesis of oral cancer. One possible mechanism is the ability of Pseudomonas to synthesize nitric oxide (NO) that modulates different cancer-related appearances such as apoptosis, cell cycle, angiogenesis, invasion, and metastasis. We think that P. aeruginosa increases the concentration of NO by converting salivary nitrite to nitric oxide, and this is how it contributes to NO-related carcinogenesis. Early diagnosis and treatment of periodontitis are very important not only for patients' oral health, but also for the prevention of OSCC development. Screening test for OSCC based on determination of salivary NO levels could be appealing and may prove to be useful assay for diagnosis and early detection of disease progression in oral cancer.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"14 2","pages":"476"},"PeriodicalIF":3.6,"publicationDate":"2020-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/61/fc/onco-14-2-476.PMC7358985.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38162780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Epithelial-mesenchymal interconversions in ovarian cancer: The levels and functions of E-cadherin in intraabdominal dissemination. 卵巢癌的上皮-间质相互转化：E-cadherin在腹腔内扩散中的水平和功能。

IF 3.1

Oncology Reviews Pub Date : 2020-05-29 eCollection Date: 2020-07-06 DOI: 10.4081/oncol.2020.475

Ricardo Roque, Filipa Costa Sousa, Margarida Figueiredo-Dias

{"title":"Epithelial-mesenchymal interconversions in ovarian cancer: The levels and functions of E-cadherin in intraabdominal dissemination.","authors":"Ricardo Roque, Filipa Costa Sousa, Margarida Figueiredo-Dias","doi":"10.4081/oncol.2020.475","DOIUrl":"10.4081/oncol.2020.475","url":null,"abstract":"The metastatic process of ovarian cancer (OC) is almost exclusively defined by direct shedding of tumor cells into the abdominal cavity, followed by clustering into multicellular aggregates and posterior peritoneal anchorage. This process relies on dynamic intercellular interactions which are modified by epithelial- mesenchymal interconversions and, therefore, E-cadherin expression variability. Although widely accepted as a tumor suppressor in many types of cancer, E-cadherin is currently known to have a dynamic expression and a much more complex role in OC. First, high E-cadherin expression is considered a sign of metaplasia in the normal ovarian epithelium, due to its association with epithelial growth factor receptor (EGFR) mediated cell proliferation. Subsequently, it is the decreased expression of E-cadherin that allows the acquisition of a more invasive phenotype, leading to the spread of primary tumor cells into the peritoneal fluid. This downregulation seems to depend on complex regulatory mechanisms, from molecular proteolysis to microenvironment interference and epigenetic regulation. E-cadherin cleavage and its resulting fragments appear to be essential to the process of dissemination and even to the formation of multicellular aggregates. Paradoxically, the maintenance of some E-cadherin expression seems to promote intercellular adhesion, resistance, and survival while decreasing cancer response to chemotherapy. Multiple studies have shown that reversing epithelial-mesenchymal transaction (EMT) and increasing E-cadherin expression prevents OC intraperitoneal dissemination, but findings that simultaneously correlate E-cadherin downregulation to higher chemotherapy sensitivity should not be ignored. Nevertheless, EMT and E-cadherin seem to have a potential interest as therapeutic targets in novel approaches to OC treatment.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"14 2","pages":"475"},"PeriodicalIF":3.1,"publicationDate":"2020-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/e9/onco-14-2-475.PMC7358986.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38162778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of Toll like receptor in progression and suppression of oral squamous cell carcinoma. Toll样受体在口腔鳞状细胞癌进展和抑制中的作用。

IF 3.6

Oncology Reviews Pub Date : 2020-05-19 eCollection Date: 2020-02-18 DOI: 10.4081/oncol.2020.456

Yash Sharma, Kumud Bala

{"title":"Role of Toll like receptor in progression and suppression of oral squamous cell carcinoma.","authors":"Yash Sharma, Kumud Bala","doi":"10.4081/oncol.2020.456","DOIUrl":"https://doi.org/10.4081/oncol.2020.456","url":null,"abstract":"Oral squamous cell carcinoma (OSCC) is one of the most common type of head and neck squamous cell carcinoma and one of the multifactorial process that consists of most contributing factors such as tobacco smoking, chewing and alcohol consumption that altered the intracellular environment. Recent studies have shown relevance of Toll like receptor (TLR) associated with carcinogenesis. This review aim's to explore that how TLR associates with progression and suppression of OSCC. This review is a classical review that has confined to articles published in the past 19 years (i.e. 2000-2019) and has summarized the perspective of the authors. 62 articles were reviewed and it was found that progression and suppression of OSCC is associated with different TLRs promoting tumor development and also inhibiting the progression of oral neoplasm. It was found that TLR2, TLR3, TLR4, TLR5, TLR7 and TLR9 are associated with tumor development i.e. in progression of OSCC, where as suppression of OSCC through TLR3 and TLR7. We authors would like to conclude that literature survey has indicated effective TLR's against OSCC development and can be explored to investigate other TLRs that can be used for therapeutic purposes in near future.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"14 1","pages":"456"},"PeriodicalIF":3.6,"publicationDate":"2020-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2020.456","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37995672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Perceived factors to providing palliative care for patients with cancer - a qualitative systematic review. 为癌症患者提供姑息治疗的感知因素-一项定性系统综述。

IF 3.6

Oncology Reviews Pub Date : 2020-05-19 eCollection Date: 2020-02-18 DOI: 10.4081/oncol.2020.463

Haydeh Heidari, Marjan Mardani-Hamooleh, Masoud Amiri

{"title":"Perceived factors to providing palliative care for patients with cancer - a qualitative systematic review.","authors":"Haydeh Heidari, Marjan Mardani-Hamooleh, Masoud Amiri","doi":"10.4081/oncol.2020.463","DOIUrl":"https://doi.org/10.4081/oncol.2020.463","url":null,"abstract":"Palliative care (PC) is one of the necessary cares given throughout a patient's experience with cancer. The aim of this study was to identify the perceived factors to providing PC for patients with cancer. Our study was a systematic review of qualitative literature. To this end, electronic databases, including CINAHL, PubMed, PsycINFO, Ovid, and Web of Science as well as Persian databases were searched and qualitative studies on the role of PC in patients with cancer published between Jan 2008 and Dec 2017 were selected. Generally, 12 studies were reviewed. A thematic synthesis approach was used to analyze the data. Exploring the selected articles, the findings on the perceived factors to providing PC for patients with cancer were categorized into three themes, including organizational factors, ethical factors, and psychological factors. This qualitative systematic review expands our knowledge about factors influencing the provision of PC for patients with cancer. It is necessary for health system managers and caregivers to pay attention to all aforesaid factors in order to improve PC for cancer patients.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"14 1","pages":"463"},"PeriodicalIF":3.6,"publicationDate":"2020-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/a0/onco-14-1-463.PMC7246343.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37995673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of cytotoxic chemotherapy-induced hand-foot syndrome. 细胞毒性化疗所致手足综合征的处理。

IF 3.6

Oncology Reviews Pub Date : 2020-05-13 eCollection Date: 2020-02-18 DOI: 10.4081/oncol.2020.442

Johannes J M Kwakman, Yannick S Elshot, Cornelis J A Punt, Miriam Koopman

{"title":"Management of cytotoxic chemotherapy-induced hand-foot syndrome.","authors":"Johannes J M Kwakman, Yannick S Elshot, Cornelis J A Punt, Miriam Koopman","doi":"10.4081/oncol.2020.442","DOIUrl":"https://doi.org/10.4081/oncol.2020.442","url":null,"abstract":"Improvements in systemic cancer treatments have resulted in more patients surviving for prolonged periods of time on treatment. This has made treatment-related toxicity and quality of life concerns increasingly relevant. Hand-foot syndrome (HFS) is a common skin reaction to systemic therapy that should be anticipated with chemotherapeutic treatments such as pegylated liposomal doxorubicin, docetaxel, and fluoropyrimidines. In this review we discuss current knowledge of the diagnosis, incidence, pathogenesis, and management of hand-foot syndrome (HFS). Although HFS is not life threatening, it can cause significant discomfort and impairment of function, especially in elderly patients, and may seriously impact quality of life. The incidence of HFS is dependent on the chemotherapeutic drug used, the treatment schedule, and the median duration of treatment. Effective measures for prevention and treatment of HFS include systemic and topical treatments, dose reductions, and switching to other drugs in the same class that are associated with lower rates of HFS. These approaches allow patients to continue cancer treatment while reducing negative impacts on quality of life. Awareness and early recognition are important to ensure timely treatment and avoidance of dose reductions or treatment discontinuation. We provide useful recommendations to guide the management of HFS in clinical practice.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"14 1","pages":"442"},"PeriodicalIF":3.6,"publicationDate":"2020-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2020.442","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37957424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 50

Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review. 前列腺特异性抗原速度在前列腺癌诊断和预后中的系统评价。

IF 3.6

Oncology Reviews Pub Date : 2020-04-30 eCollection Date: 2020-02-18 DOI: 10.4081/oncol.2020.449

Arslaan Javaeed, Sanniya Khan Ghauri, Abdellatif Ibrahim, Mohamed Fahmy Doheim

引用次数: 4

Elucidating the pathogenic and biomarker potentials of FOXG1 in glioblastoma. 阐明FOXG1在胶质母细胞瘤中的致病和生物标志物潜力。

IF 3.6

Oncology Reviews Pub Date : 2020-04-30 eCollection Date: 2020-02-18 DOI: 10.4081/oncol.2020.444

Seidu A Richard, Zhou Jia-Hao

{"title":"Elucidating the pathogenic and biomarker potentials of FOXG1 in glioblastoma.","authors":"Seidu A Richard, Zhou Jia-Hao","doi":"10.4081/oncol.2020.444","DOIUrl":"https://doi.org/10.4081/oncol.2020.444","url":null,"abstract":"Glioblastoma (GB) is an extremely pugnacious brain cancer originating from neural stem (NS) cell-like cells. Forkhead box G1 (FOXG1; previously recognized as BF-1, qin, Chicken Brain Factor 1, or XBF-1 and renamed FOXG1 for mouse and human, and FoxG1 for other chordates) is an evolutionary preserved transcription factor driven from the forkhead box group of proteins FOXG1 modulates the speed of neurogenesis by maintaining progenitor cells in a proliferative mode as well as obstructing their differentiation into neurons during the initial periods of cortical formation. FOXG1 has been implicated in the formation of central nervous system (CNS) tumors and precisely GBs. Pathophysiologically, joint actions of FOXG1 and phosphatidylinositol- 3-kinases (PI3K) intermediate in intrinsic resistance of human GB cells to transforming growth factor-beta (TGF-β) stimulation of cyclin-dependent kinase inhibitor 1(p21Cip1) as well as growth inhibition. FOXG1 and NOTCH signaling pathways may functionally interrelate at different stages to facilitate gliomagenesis. Furthermore, FoxG1 actively contributed to the formation of transcription suppression complexes with corepressors of the Groucho/transducin-like Enhancer of split (Gro/TLEs). Also, FOXG1 was stimulated by Gro/TLE1 and abridged by Grg6. FOXG1 silencing in brain tumor-initiating cells (BTICs) also resulted in diminished secretion of markers characteristic undifferentiated natural neural stem/progenitor cells (NSPC) states, such as Oligodendrocyte transcription factor (OLIG2), (sex determining region Y)-box 2. (SOX2) and B lymphoma Mo-MLV insertion region 1 homolog (BMI1). This review therefore focuses on the pathogenic and biomarker potentials of FOXG1 in GB.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"14 1","pages":"444"},"PeriodicalIF":3.6,"publicationDate":"2020-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2020.444","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37923419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

EPAC2: A new and promising protein for glioma pathogenesis and therapy. EPAC2:神经胶质瘤发病机制和治疗的新蛋白。

IF 3.6

Oncology Reviews Pub Date : 2020-04-30 eCollection Date: 2020-02-18 DOI: 10.4081/oncol.2020.446

Seidu A Richard

{"title":"EPAC2: A new and promising protein for glioma pathogenesis and therapy.","authors":"Seidu A Richard","doi":"10.4081/oncol.2020.446","DOIUrl":"https://doi.org/10.4081/oncol.2020.446","url":null,"abstract":"Gliomas are prime brain cancers which are initiated by malignant modification of neural stem cells, progenitor cells and differentiated glial cells such as astrocyte, oligodendrocyte as well as ependymal cells. Exchange proteins directly activated by cAMP (EPACs) are crucial cyclic adenosine 3',5'-monophosphate (cAMP)-determined signaling pathways. Cyclic AMP-intermediated signaling events were utilized to transduce protein kinase A (PKA) leading to the detection of EPACs or cAMP-guanine exchange factors (cAMP-GEFs). EPACs have been detected as crucial proteins associated with the pathogenesis of neurological disorders as well as numerous human diseases. EPAC proteins have two isoforms. These isoforms are EPAC1 and EPAC2. EPAC2 also known as Rap guanine nucleotide exchange factor 4 (RAPGEF4) is generally expression in all neurites. Higher EAPC2 levels was detected in the cortex, hippocampus as well as striatum of adult mouse brain. Activation as well as over-secretion of EPAC2 triggers apoptosis in neurons and EPAC-triggered apoptosis was intermediated via the modulation of Bcl-2 interacting member protein (BIM). EPAC2 secretory levels has proven to be more in low-grade clinical glioma than high-grade clinical glioma. This review therefore explores the effects of EPAC2/RAPGEF4 on the pathogenesis of glioma instead of EPAC1 because EPAC2 and not EPAC1 is predominately expressed in the brain. Therefore, EPAC2 is most likely to modulate glioma pathogenesis rather than EPAC1.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"14 1","pages":"446"},"PeriodicalIF":3.6,"publicationDate":"2020-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2020.446","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37923332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Periocular basal cell carcinoma - clinical perspectives. 眼周基底细胞癌的临床观点。

IF 3.6

Oncology Reviews Pub Date : 2020-04-30 eCollection Date: 2020-02-18 DOI: 10.4081/oncol.2020.420

Alena Furdova, Karolina Kapitanova, Alexandra Kollarova, Juraj Sekac

引用次数: 16